Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

After reviewing a large number of published clinical studies on the use of various forms of cannabis (marijuana) to treat neuropathic pain, the authors of a recent study concluded that there was limited evidence to suggest any ben...

View Blog Post
Blog Post

The current approach to pharmacotherapy in the United States has had mixed success. Prescription rates continue to rise with an estimated total of

View Blog Post
Blog Post

Recently announced research from Aarhaus University in Denmark may be the first step in making key improvements to cholesterol-lowering medications. As detailed in the World Pharma News story

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up